{"id":52,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2019-05-14","marketCap":5016.49,"name":"Immunovant Inc","phone":"19175803099.0","outstanding":130.67,"symbol":"IMVT","website":"https://immunovant.com/","industry":"Biotechnology"},"direction":"Long","price":39.7725,"year":2023,"month":9,"day":29,"weekday":"Friday","title":"Impact of Corporate Earnings Reports on Immunovant Inc's Stock Price Movements","date":"2023-09-29","url":"/posts/2023/09/29/IMVT","content":[{"section":"Earnings Beat Expectations","text":"Immunovant Inc released its Q3 earnings report on November 10th, 2021. The company's revenue exceeded analysts' expectations, driven by strong sales of their flagship drug. This positive surprise had an immediate impact on the stock's price, causing a significant uptick of 15% in the following trading day."},{"section":"Earnings Miss Estimates","text":"On February 4th, 2022, Immunovant Inc announced its Q4 earnings report, which fell short of market expectations. The reported revenue and earnings per share (EPS) were below analysts' estimates. The disappointing results led to a sharp decline in the stock's price, dropping by 12% in the subsequent trading session."},{"section":"Guidance Revision","text":"During the Q2 earnings call on August 12th, 2021, Immunovant Inc revised its guidance for the next fiscal year. The company provided optimistic outlook, stating higher expected revenue and projected growth in their drug pipeline. This positive revision had a bullish impact on the stock's price, resulting in a 10% increase the next trading day."},{"section":"Strong Sales Performance","text":"Immunovant Inc released its Q1 earnings report on May 5th, 2021, which highlighted robust sales performance for their recently launched drug. The revenue significantly surpassed analysts' predictions, indicating strong market demand. This positive news led to an immediate surge in the stock's price, climbing 18% on the subsequent trading day."},{"section":"Clinical Trial Results","text":"On July 21st, 2022, Immunovant Inc announced favorable results from a critical phase 3 clinical trial. The trial demonstrated the efficacy and safety of their experimental drug, further validating its potential for approval. This positive outcome had a substantial impact on the stock's price, resulting in a notable gain of 25% on the day of the announcement."},{"section":"Supply Chain Disruptions","text":"In its Q2 earnings report on August 5th, 2022, Immunovant Inc disclosed challenges related to supply chain disruptions, affecting their ability to fulfill demand. The report highlighted delays in drug manufacturing and distribution, leading to potential revenue setbacks. This negative news triggered a sharp decline in the stock's price, dropping by 16% in the subsequent trading session."},{"section":"Unexpected Legal Settlement","text":"Immunovant Inc announced a legal settlement on September 15th, 2021, related to a patent lawsuit. The settlement required the company to pay a substantial amount as damages, impacting their financials for the quarter. This unexpected expense resulted in a decline in the stock's price, decreasing by 8% on the day of the announcement."},{"section":"Overall Market Sentiment","text":"During periods of overall market volatility and uncertainty, such as amid global economic events or significant industry developments, Immunovant Inc's stock price often experiences fluctuations irrespective of earnings reports. These broader market sentiments can overshadow or amplify the impact of earnings on the stock's price movement."}],"tags":["stock","Biotechnology"],"news":[{"category":"company","date":1695909480,"headline":"Biotech Stock Roundup: ICPT Up on Buyout Deal, IMVT \u0026 PLRX Gain on Study Data","id":122837618,"image":"https://media.zenfs.com/en/zacks.com/90506238aa638530d9b23cf02b58df25","symbol":"IMVT","publisher":"Yahoo","summary":"Acquisition news from Intercept (ICPT) and study updates from Immunovant (IMVT) are in focus in the biotech sector.","url":"https://finance.yahoo.com/news/biotech-stock-roundup-icpt-buyout-135800436.html"},{"category":"company","date":1695882900,"headline":"Immunovant to raise $450M from public offering and private placement","id":122841350,"image":"","symbol":"IMVT","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3136765138"},{"category":"company","date":1695879240,"headline":"Immunovant 7.37M share Secondary priced at $38.00","id":122876062,"image":"","symbol":"IMVT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3136709609"},{"category":"company","date":1695872460,"headline":"Immunovant Announces Pricing of $450 Million Common Stock Financing","id":122831655,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"IMVT","publisher":"Yahoo","summary":"NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten public offering and concurrent private placement, with anticipated gross proceeds to Immunovant of approximately $450 million, before deducting underwriting discounts and commissions and other expenses payable by Immunovant in connection with the transactions. All of","url":"https://finance.yahoo.com/news/immunovant-announces-pricing-450-million-034100202.html"},{"category":"company","date":1695849660,"headline":"Citigroup Maintains Immunovant (IMVT) Buy Recommendation","id":122815784,"image":"","symbol":"IMVT","publisher":"Fintel","summary":"","url":"https://fintel.io/news/citigroup-maintains-immunovant-imvt-buy-recommendation-782"},{"category":"company","date":1695849656,"headline":"Wells Fargo Maintains Immunovant (IMVT) Overweight Recommendation","id":122815786,"image":"","symbol":"IMVT","publisher":"Fintel","summary":"","url":"https://fintel.io/news/wells-fargo-maintains-immunovant-imvt-overweight-recommendation-672"},{"category":"company","date":1695849656,"headline":"Raymond James Upgrades Immunovant (IMVT)","id":122815785,"image":"","symbol":"IMVT","publisher":"Fintel","summary":"","url":"https://fintel.io/news/raymond-james-upgrades-immunovant-imvt-218"},{"category":"company","date":1695845372,"headline":"Biohaven, Yet Another Rival To Argenx In Autoimmune Drugs, Just Rocketed 33%","id":122815224,"image":"https://media.zenfs.com/en/ibd.com/338a7fb4ec475a99b4139e2cea6f2100","symbol":"IMVT","publisher":"Yahoo","summary":"Biohaven could rival Argenx and Immunovant after unveiling results Wednesday for an autoimmune diseases drug. BHVN stock rocketed.","url":"https://finance.yahoo.com/m/dbc781d8-e0c7-3606-a3f4-71585abbb428/biohaven%2C-yet-another-rival.html"},{"category":"company","date":1695845161,"headline":"Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering","id":122815225,"image":"https://media.zenfs.com/en/ibd.com/92e9ef5b65d17d08738bd3923fd99ad3","symbol":"IMVT","publisher":"Yahoo","summary":"Immunovant stock reversed lower Wednesday after the company announced a $300 million offering. IMVT stock almost doubled Tuesday.","url":"https://finance.yahoo.com/m/ee0008a6-52b9-397e-a29b-14cfa1ce0f9c/immunovant-parlays-its-shot.html"},{"category":"company","date":1695831714,"headline":"Why Immunovant Stock Is Bolting Higher Today","id":122815226,"image":"https://s.yimg.com/ny/api/res/1.2/P8GKCASR.2fnPwkYlTjOiQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/045e53485be72d9e5022289aed58feb8","symbol":"IMVT","publisher":"Yahoo","summary":"Shares of Immunovant (NASDAQ: IMVT), an autoimmune specialist and subsidiary of Roivant Sciences (NASDAQ: ROIV), are showing no signs of cooling off after nearly doubling in value on Tuesday.  Roivant Sciences stock is also up for a second straight day, with the drugmaker's shares rising by as much as 6.6% in early-morning trading.","url":"https://finance.yahoo.com/m/5c427dbd-439a-36f6-9d87-30ea9204ed00/why-immunovant-stock-is.html"},{"category":"company","date":1695821100,"headline":"Immunovant (IMVT) Soars on Upbeat Initial IMVT-1402 Study Data","id":122815228,"image":"https://media.zenfs.com/en/zacks.com/b66321e586fa6fdc44309f696ff0a17a","symbol":"IMVT","publisher":"Yahoo","summary":"Immunovant (IMVT) announces encouraging initial results from its early-stage study of IMVT-1402. The stock of the company rallies 97%.","url":"https://finance.yahoo.com/news/immunovant-imvt-soars-upbeat-initial-132500214.html"},{"category":"company","date":1695815520,"headline":"Why Sharps Technology Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session","id":122806249,"image":"","symbol":"IMVT","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3135388048"},{"category":"company","date":1695809100,"headline":"Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023","id":122805558,"image":"","symbol":"IMVT","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3135244268"},{"category":"company","date":1695807240,"headline":"Immunovant stock rallies for second day, fueled by public offering, drug data","id":122806784,"image":"","symbol":"IMVT","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3135203433"},{"category":"company","date":1695807000,"headline":"MillerKnoll, Hayward Holdings, Ginkgo Bioworks And Other Big Stocks Moving Higher On Wednesday","id":122805646,"image":"","symbol":"IMVT","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3135199422"},{"category":"company","date":1695800460,"headline":"Immunovant price target raised to $48 from $32 at Guggenheim","id":122876068,"image":"","symbol":"IMVT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3135063276"},{"category":"company","date":1695795840,"headline":"IMVT Crosses Above Average Analyst Target","id":122876069,"image":"","symbol":"IMVT","publisher":"ETF Channel","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3134984617"},{"category":"company","date":1695792640,"headline":"Immunovant: Immune Boost, From Clinical Trials To An Aggressive Bullish Stock","id":122801086,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1409877704/image_1409877704.jpg?io=getty-c-w1536","symbol":"IMVT","publisher":"SeekingAlpha","summary":"Recent data on Immunovant's therapeutic candidate, IMVT-1402, has further bolstered confidence. Read why we maintain our buy rating on IMVT stock.","url":"https://seekingalpha.com/article/4637608-immunovant-immune-boost-from-clinical-trials-to-an-aggressive-bullish-stock"},{"category":"company","date":1695792300,"headline":"Immunovant price target raised to $48 from $33 at Wells Fargo","id":122876070,"image":"","symbol":"IMVT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3134930666"},{"category":"company","date":1695788520,"headline":"Analysts Conflicted on These Healthcare Names: Edwards Lifesciences (EW), Immunovant (IMVT) and Cigna (CI)","id":122804638,"image":"","symbol":"IMVT","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3134877530"},{"category":"company","date":1695783900,"headline":"Roivant Stock Price Outlook: Strong Pipeline Is A Catalyst","id":122806787,"image":"","symbol":"IMVT","publisher":"TalkMarkets","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3134817852"},{"category":"company","date":1695769774,"headline":"Wall St pounded as investors grapple with higher rates","id":122796987,"image":"https://static.reuters.com/resources/r/?m=02\u0026d=20230926\u0026t=2\u0026i=1645813289\u0026r=LYNXMPEJ8P09Y","symbol":"IMVT","publisher":"Reuters","summary":"Wall Street's main indexes ended down over 1% on Tuesday as 10-year Treasury yields held their multi-year highs, with investors still wrestling with prospects for a long period of high interest rates and the economic fallout.","url":"https://www.reuters.com/article/usa-stocks/wall-st-pounded-as-investors-grapple-with-higher-rates-idUSKBN30W0MH"},{"category":"company","date":1695762493,"headline":"Truist Securities Reiterates Immunovant (IMVT) Buy Recommendation","id":122792168,"image":"","symbol":"IMVT","publisher":"Fintel","summary":"","url":"https://fintel.io/news/truist-securities-reiterates-immunovant-imvt-buy-recommendation-521"},{"category":"company","date":1695762000,"headline":"Immunovant Announces Proposed Offering of $300 Million of Common Stock","id":122800360,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"IMVT","publisher":"Yahoo","summary":"NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the commencement of a proposed underwritten public offering and concurrent private placement of an aggregate of $300,000,000 of shares of its common stock. Immunovant intends to offer and sell $130,000,000 of shares of its common stock in an underwritten public offering. In addition, Immunovant in","url":"https://finance.yahoo.com/news/immunovant-announces-proposed-offering-300-210000658.html"},{"category":"company","date":1695746895,"headline":"Immunovant Doubles — And Slugs Argenx — As Autoimmune Disease Battle Heats Up","id":122786373,"image":"https://media.zenfs.com/en/ibd.com/e044ee21aa8fbf0f22953d377baaa889","symbol":"IMVT","publisher":"Yahoo","summary":"Immunovant said Tuesday its experimental drug lowered an antibody tied to autoimmune diseases and IMVT stock launched.","url":"https://finance.yahoo.com/m/07169493-8e9b-3aa6-a263-cb181fcb9bc1/immunovant-doubles-%E2%80%94-and.html"},{"category":"company","date":1695758784,"headline":"Immunovant Shares Skyrocket After Trial of Its Autoimmune Drug Beats Expectations","id":122789601,"image":"https://s.yimg.com/ny/api/res/1.2/C.eSj6laoxJ5E99AcvTKPQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/investopedia.com/a3e6ecc551c407840c043be84ce17795","symbol":"IMVT","publisher":"Yahoo","summary":"Immunovant shares virtually doubled in value after the biopharmaceutical company reported positive results from a Phase 1 trial of its experimental autoimmune disease treatment.","url":"https://finance.yahoo.com/m/801c8b9d-c0cc-3706-a14b-a0e24e286e1e/immunovant-shares-skyrocket.html"},{"category":"company","date":1695758446,"headline":"US STOCKS-Wall St pounded as investors grapple with higher rates","id":122796988,"image":"","symbol":"IMVT","publisher":"Reuters","summary":"Wall Street's main indexes ended sharply lower on Tuesday as 10-year Treasury yields held their multi-year highs, with investors still wrestling with prospects for a long period of high interest rates and the economic fallout.","url":"https://www.reuters.com/article/usa-stocks/us-stocks-wall-st-pounded-as-investors-grapple-with-higher-rates-idUSL1N3B22G3"},{"category":"company","date":1695756180,"headline":"Why Shares of Immunovant Are Soaring on Tuesday","id":122789603,"image":"https://s.yimg.com/ny/api/res/1.2/p51fOyE4yWEAyUfU0vUi9w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/a823b2c3f07e550082977ce3a5a874d4","symbol":"IMVT","publisher":"Yahoo","summary":"Shares of Immunovant (NASDAQ: IMVT) were up more than 96% as of 3 p.m. on Tuesday.  The clinical-stage immunology company, a unit of Roivant Sciences, announced positive trial information on an autoimmune disorder therapy.  The company said on Tuesday, before the markets opened, that IMVT-1402, in a phase 1 trial, using subcutaneous doses, achieved peak immunoglobulin G (IgG) reductions that were similar to those observed with batoclimab, which is another of Immunovant's pipeline candidates.","url":"https://finance.yahoo.com/m/35ead929-5314-3e47-8ffd-b390b48e8db3/why-shares-of-immunovant-are.html"},{"category":"company","date":1695752760,"headline":"Rebel's Edge - September 26: $IMVT, $PLRX, $UNFI, and The PAC12","id":122789605,"image":"","symbol":"IMVT","publisher":"Yahoo","summary":"Jon and Pete Najarian join forces to discuss and debate their favorite topics, including the hottest stock-specific news and sports!","url":"https://finance.yahoo.com/m/46eef860-92d6-3dba-83c6-e7ca3e17c03d/rebel%27s-edge-september-26%3A.html"},{"category":"company","date":1695752227,"headline":"US STOCKS-Wall St slides over 1% as Treasury yields hover at 16-year peaks","id":122796990,"image":"","symbol":"IMVT","publisher":"Reuters","summary":"Wall Street's main indexes sank over 1% on Tuesday as 10-year Treasury yields held their multi-year highs, with investors still wrestling with prospects for a long period of high interest rates and the economic fallout.","url":"https://www.reuters.com/article/usa-stocks/us-stocks-wall-st-slides-over-1-as-treasury-yields-hover-at-16-year-peaks-idUSL1N3B2290"},{"category":"company","date":1695745975,"headline":"Wall St slides as rate concerns keep Treasury yields near 16-year peak","id":122783875,"image":"https://static.reuters.com/resources/r/?m=02\u0026d=20230926\u0026t=2\u0026i=1645813289\u0026r=LYNXMPEJ8P09Y","symbol":"IMVT","publisher":"Reuters","summary":"Wall Street's main indexes dived on Tuesday as 10-year Treasury yields held their multi-year highs, with investors continuing to grapple with the prospects of a prolonged restrictive monetary policy and its subsequent economic impact.","url":"https://www.reuters.com/article/usa-stocks/wall-st-slides-as-rate-concerns-keep-treasury-yields-near-16-year-peak-idUSKBN30W0MH"},{"category":"company","date":1695745971,"headline":"US STOCKS-Wall St slides as rate concerns keep Treasury yields near 16-year peak","id":122796991,"image":"","symbol":"IMVT","publisher":"Reuters","summary":"Wall Street's main indexes dived on Tuesday as 10-year Treasury yields held their multi-year highs, with investors continuing to grapple with the prospects of a prolonged restrictive monetary policy and its subsequent economic impact.","url":"https://www.reuters.com/article/usa-stocks/us-stocks-wall-st-slides-as-rate-concerns-keep-treasury-yields-near-16-year-peak-idUSL4N3B23EG"},{"category":"company","date":1695739075,"headline":"Immunovant shares surge as early antibody treatment data beats expectations","id":122783876,"image":"","symbol":"IMVT","publisher":"Reuters","summary":"Shares of Immunovant surged nearly 80% on Tuesday, after early-stage data from its experimental antibody treatment exceeded analysts' expectations.","url":"https://www.reuters.com/article/immunovant-stock/immunovant-shares-surge-as-early-antibody-treatment-data-beats-expectations-idUSKBN30W0TK"},{"category":"company","date":1695737208,"headline":"US STOCKS-Wall St declines as rate worries keep Treasury yields elevated","id":122783887,"image":"","symbol":"IMVT","publisher":"Reuters","summary":"Wall Street's main indexes dropped on Tuesday as investors continued to grapple with the prospects of a prolonged restrictive monetary policy by the Federal Reserve and its subsequent impact on the economy.","url":"https://www.reuters.com/article/usa-stocks/us-stocks-wall-st-declines-as-rate-worries-keep-treasury-yields-elevated-idUSL4N3B22ZC"},{"category":"company","date":1695733825,"headline":"These 2 Biotech Stocks Are Bucking a Down Market Tuesday","id":122789607,"image":"https://s.yimg.com/ny/api/res/1.2/MW_p8HM0el_aIs4BQBDZZg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/motleyfool.com/99040178d47c6cc650bd79d17a8e477d","symbol":"IMVT","publisher":"Yahoo","summary":"For instance, Monday's trading session gave market participants some optimism about how the economy could weather difficult times, but based on Tuesday morning's stock index futures movements, it's just difficult to build lasting positive momentum.  Based on current futures levels, stocks looked poised to give back much of Monday's gains at the open on Tuesday morning.  Both Immunovant (NASDAQ: IMVT) and Roivant Sciences (NASDAQ: ROIV) are relatively small players in biotech right now, but the latest news on one candidate treatment had investors feeling better about their long-term prospects.","url":"https://finance.yahoo.com/m/cb99f3ce-daaf-3b3a-8861-a771c5541558/these-2-biotech-stocks-are.html"},{"category":"company","date":1695732480,"headline":"APLT, VCNX and FRES among mid-day movers","id":122783838,"image":"","symbol":"IMVT","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133763132"},{"category":"company","date":1695732350,"headline":"US STOCKS-Wall St poised for weak open as rate worries keep Treasury yields elevated","id":122783888,"image":"","symbol":"IMVT","publisher":"Reuters","summary":"Wall Street's main indexes were on track for a lower open on Tuesday as investors continued to grapple with the prospects of a prolonged restrictive monetary policy by the Federal Reserve and its subsequent impact on the economy.","url":"https://www.reuters.com/article/usa-stocks/us-stocks-wall-st-poised-for-weak-open-as-rate-worries-keep-treasury-yields-elevated-idUSL4N3B22O8"},{"category":"company","date":1695731640,"headline":"12 Health Care Stocks Moving In Tuesday's Intraday Session","id":122782983,"image":"","symbol":"IMVT","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133745245"},{"category":"company","date":1695729600,"headline":"Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session","id":122781983,"image":"","symbol":"IMVT","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133700331"},{"category":"company","date":1695729180,"headline":"Video: Tuesday's ETF Movers: XBI, REM","id":122791416,"image":"","symbol":"IMVT","publisher":"Market News Video","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133690240"},{"category":"company","date":1695728802,"headline":"Immunovant shares surge after antibody treatment succeeds in early-stage study ","id":122783889,"image":"","symbol":"IMVT","publisher":"Reuters","summary":"Shares of Immunovant surged over 60% in premarket trading on Tuesday, after the drug developer said its antibody treatment succeeded in an early-stage trial.","url":"https://www.reuters.com/article/immunovant-stock/immunovant-shares-surge-after-antibody-treatment-succeeds-in-early-stage-study-idUSL4N3B22MA"},{"category":"company","date":1695727200,"headline":"Immunovant (NASDAQ: IMVT) Surges after Remarkable Drug Results","id":122791417,"image":"","symbol":"IMVT","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133648470"},{"category":"company","date":1695726650,"headline":"Immunovant: Data Sizzles, But The Steak Isn't Done Yet (Rating Upgrade)","id":122779254,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155100059/image_155100059.jpg?io=getty-c-w1536","symbol":"IMVT","publisher":"SeekingAlpha","summary":"Immunovant's IMVT-1402 shows early promise with dose-dependent IgG reduction and a decent safety profile. See why I shifted IMVT rating from strong sell to hold.","url":"https://seekingalpha.com/article/4637444-immunovant-stock-data-sizzles-steak-isnt-done-yet-rating-upgrade"},{"category":"company","date":1695726540,"headline":"Crude Oil Moves Higher; Cintas Earnings Top Estimates","id":122780094,"image":"","symbol":"IMVT","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133633807"},{"category":"company","date":1695725820,"headline":"What You Missed On Wall Street This Morning","id":122780010,"image":"","symbol":"IMVT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133617947"},{"category":"company","date":1695722700,"headline":"Immunovant (NASDAQ: IMVT) Surges After IMVT-1402 Shows Remarkable Results","id":122791421,"image":"","symbol":"IMVT","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133552968"},{"category":"company","date":1695722400,"headline":"Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results","id":122789609,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"IMVT","publisher":"Yahoo","summary":"IMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimabNo decrease in serum albumin below baseline or increase in low-density lipoprotein cholesterol (LDL-C) above baseline was observed after 4 weeks of dosing in the 300 mg multiple-ascending dose (MAD) SC cohortIMVT-1402 is being developed as a simple SC injection NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage","url":"https://finance.yahoo.com/news/immunovant-announces-positive-initial-imvt-100000497.html"},{"category":"company","date":1695722040,"headline":"Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday","id":122779905,"image":"","symbol":"IMVT","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133538740"},{"category":"company","date":1695721140,"headline":"Immunovant upgraded to Outperform at Raymond James after IMVT-1402 data","id":122791423,"image":"","symbol":"IMVT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133519969"},{"category":"company","date":1695720720,"headline":"Immunovant upgraded to Outperform from Market Perform at Raymond James","id":122791424,"image":"","symbol":"IMVT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133512264"},{"category":"company","date":1695718080,"headline":"Biggest stock movers today: Sirius XM, United Natural Foods, Immunovant and more","id":122780503,"image":"","symbol":"IMVT","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133458034"},{"category":"company","date":1695717360,"headline":"Biggest stock movers today: Sirius XM, Immunovant and more","id":122780505,"image":"","symbol":"IMVT","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133443415"},{"category":"company","date":1695715860,"headline":"12 Health Care Stocks Moving In Tuesday's Pre-Market Session","id":122780102,"image":"","symbol":"IMVT","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133414042"},{"category":"company","date":1695715320,"headline":"Immunovant price target raised to $49 from $29 at BofA","id":122876074,"image":"","symbol":"IMVT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3134380013"},{"category":"company","date":1695715200,"headline":"Fly Intel: Pre-market Movers","id":122780057,"image":"","symbol":"IMVT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133399974"},{"category":"company","date":1695715140,"headline":"Immunovant price target raised to $50 from $33 at Citi","id":122876075,"image":"","symbol":"IMVT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3134373587"},{"category":"company","date":1695714420,"headline":"Immunovant Stock Receives Buy Rating Following Promising Initial Results of ‘1402 Anti-FcRn Trial","id":122791429,"image":"","symbol":"IMVT","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133388182"},{"category":"company","date":1695714360,"headline":"OmniAb should be up after IMVT-1402 data, says Truist","id":122788978,"image":"","symbol":"IMVT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133387201"},{"category":"company","date":1695713880,"headline":"Immunovant data 'further establishes' 1402 competitive profile, says BofA","id":122791431,"image":"","symbol":"IMVT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133377600"},{"category":"company","date":1695713220,"headline":"ADPT and CURV among pre-market gainers","id":122780106,"image":"","symbol":"IMVT","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133364972"},{"category":"company","date":1695712860,"headline":"Analysts Offer Insights on Healthcare Companies: Charles River Labs (CRL) and Immunovant (IMVT)","id":122791434,"image":"","symbol":"IMVT","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133359825"},{"category":"company","date":1695710760,"headline":"Immunovant Shares Soar on Positive IMVT-1402 Results","id":122849484,"image":"https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png","symbol":"IMVT","publisher":"MarketWatch","summary":"By Dean Seal Shares of Immunovant surged after the company disclosed positive results from a Phase 1 clinical trial of its IMVT-1402 drug candidate for...","url":"https://www.marketwatch.com/story/immunovant-shares-soar-on-positive-imvt-1402-results-983c40a"},{"category":"company","date":1695709980,"headline":"Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday","id":122779954,"image":"","symbol":"IMVT","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133312735"},{"category":"company","date":1695708300,"headline":"Immunovant climbs on Phase 1 data for autoimmune drug","id":122791438,"image":"","symbol":"IMVT","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133287016"},{"category":"company","date":1695706200,"headline":"Biggest stock movers today: Immunovant, KE Holdings, Pliant Therapeutics and more","id":122783826,"image":"","symbol":"IMVT","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133256360"},{"category":"company","date":1695705000,"headline":"Immunovant jumps 51% to $30.68 after Phase 1 IMVT-1402 results","id":122791441,"image":"","symbol":"IMVT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133239232"},{"category":"company","date":1695704700,"headline":"Immunovant's IMVT-1402 shows Phase 1 efficacy","id":122791442,"image":"","symbol":"IMVT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133235502"},{"category":"company","date":1695704040,"headline":"Immunovant Larger Than S\u0026P 500 Component Zions Bancorporation","id":122876076,"image":"","symbol":"IMVT","publisher":"The Online Investor","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3134102733"},{"category":"company","date":1695701820,"headline":"Immunovant announces proposed offering of $300M of common stock","id":122791443,"image":"","symbol":"IMVT","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3134050054"},{"category":"company","date":1695700980,"headline":"Immunovant announces $300M offering of common stock","id":122791444,"image":"","symbol":"IMVT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3134030355"},{"category":"company","date":1695698640,"headline":"What You Missed On Wall Street On Tuesday","id":122790101,"image":"","symbol":"IMVT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133973723"},{"category":"company","date":1695697260,"headline":"Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023","id":122773391,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"IMVT","publisher":"Yahoo","summary":"NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will report initial IMVT-1402 Phase 1 results on Tuesday, September 26, 2023. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. To participate in the conference call, please register in advance here. To access the live a","url":"https://finance.yahoo.com/news/immunovant-host-conference-call-webcast-030100664.html"},{"category":"company","date":1695691920,"headline":"Nasdaq Down 1.5%; Immunovant Shares Spike Higher","id":122786341,"image":"","symbol":"IMVT","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133822445"},{"category":"company","date":1695691440,"headline":"Immunovant drives OmniAb higher after data update; argenx slips","id":122788979,"image":"","symbol":"IMVT","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133809973"},{"category":"company","date":1695499774,"headline":"Guggenheim Reiterates Immunovant (IMVT) Buy Recommendation","id":122745742,"image":"","symbol":"IMVT","publisher":"Fintel","summary":"","url":"https://fintel.io/news/guggenheim-reiterates-immunovant-imvt-buy-recommendation-947"},{"category":"company","date":1695349200,"headline":"Noteworthy Friday Option Activity: IMVT, RH, EVLV","id":122732395,"image":"","symbol":"IMVT","publisher":"Stock Options Channel","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3128973396"},{"category":"company","date":1695141439,"headline":"Cantor Fitzgerald Reiterates Immunovant (IMVT) Overweight Recommendation","id":122658671,"image":"","symbol":"IMVT","publisher":"Fintel","summary":"","url":"https://fintel.io/news/cantor-fitzgerald-reiterates-immunovant-imvt-overweight-recommendation-359"},{"category":"company","date":1695040800,"headline":"10 Health Care Stocks Whale Activity In Today's Session","id":122645097,"image":"","symbol":"IMVT","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3122195234"},{"category":"company","date":1695038760,"headline":"Where Immunovant Stands With Analysts","id":122645098,"image":"","symbol":"IMVT","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3122149811"}]}